NCT06662019View on ClinicalTrials.gov

Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions
Healthy
Interventions
DRUG

N-IP-00001 inhalation solution

Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).

DRUG

0.9% NaCl isotonic saline solution

Nebulized treatment consisting of 0.9% saline solution.

Trial Locations (2)

6009

Linear Clinical Research Ltd, Perth

6027

Linear Clinical Research Ltd, Perth

All Listed Sponsors
lead

NeoTrials Pty Ltd

INDUSTRY

NCT06662019 - Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers. | Biotech Hunter | Biotech Hunter